J
J. De-Bono
Researcher at The Royal Marsden NHS Foundation Trust
Publications - 39
Citations - 2453
J. De-Bono is an academic researcher from The Royal Marsden NHS Foundation Trust. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 18, co-authored 39 publications receiving 2039 citations. Previous affiliations of J. De-Bono include Institute of Cancer Research & University of Texas Health Science Center at San Antonio.
Papers
More filters
Journal ArticleDOI
Genomic correlates of clinical outcome in advanced prostate cancer.
Wassim Abida,Joanna Cyrta,Joanna Cyrta,Glenn Heller,Davide Prandi,Joshua Armenia,Ilsa Coleman,Marcin Cieslik,Matteo Benelli,Dan R. Robinson,Eliezer M. Van Allen,Eliezer M. Van Allen,Andrea Sboner,Tarcisio Fedrizzi,Juan Miguel Mosquera,Brian D. Robinson,Navonil De Sarkar,Lakshmi P. Kunju,Scott A. Tomlins,Yi-Mi Wu,Daniel Nava Rodrigues,Massimo Loda,Massimo Loda,Anuradha Gopalan,Victor E. Reuter,Colin C. Pritchard,Joaquin Mateo,Diletta Bianchini,Susana Miranda,Suzanne Carreira,Pasquale Rescigno,Julie Filipenko,Jacob Vinson,Robert B. Montgomery,Himisha Beltran,Himisha Beltran,Elisabeth I. Heath,Howard I. Scher,Philip W. Kantoff,Mary-Ellen Taplin,Nikolaus Schultz,J. De-Bono,Francesca Demichelis,Peter S. Nelson,Mark A. Rubin,Mark A. Rubin,Arul M. Chinnaiyan,Charles L. Sawyers +47 more
TL;DR: This large analysis integrating mCRPC genomics with histology and clinical outcomes identifies RB1 genomic alteration as a potent predictor of poor outcome, and is a community resource for further interrogation of clinical and molecular associations.
Journal ArticleDOI
Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.
Alain C. Mita,Louis Denis,Eric K. Rowinsky,J. De-Bono,Andrew Goetz,Leonel Ochoa,Bahram Forouzesh,Muralidhar Beeram,Amita Patnaik,Kathleen Molpus,Dorothée Semiond,Michele Besenval,Anthony W. Tolcher +12 more
TL;DR: The general tolerability and encouraging antitumor activity in taxane-refractory patients warrant further evaluations of XRP6258.
Journal ArticleDOI
A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors
Nicola Steele,Jane A. Plumb,Laura Vidal,Jette Tjørnelund,Poul Knoblauch,Annie Rasmussen,Chean Eng Ooi,P. Buhl-Jensen,Robert S. Brown,T.R. Jeffry Evans,J. De-Bono +10 more
TL;DR: I.v. belinostat is well tolerated, exhibits dose-dependent pharmacodynamic effects, and has promising antitumor activity in patients with advanced refractory solid tumors.
Journal ArticleDOI
A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer.
Laura Vidal,Hardev Pandha,Timothy A. Yap,C L White,K Twigger,Richard G. Vile,Richard G. Vile,Alan Melcher,Matthew C. Coffey,Kevin J. Harrington,J. De-Bono +10 more
TL;DR: Oncolytic reovirus can be safely and repeatedly administered by i.v. injection at doses up to 3 × 1010 TCID50 for 5 days every 4 weeks without evidence of severe toxicities, and is a safe agent that warrants further evaluation in phase II studies.
Journal ArticleDOI
Complex patterns of ETS gene alteration arise during cancer development in the human prostate.
Jeremy Clark,Gerhardt Attard,Gerhardt Attard,Sameer Jhavar,Penny Flohr,Alison Reid,Alison Reid,J. De-Bono,J. De-Bono,Rosalind A. Eeles,Rosalind A. Eeles,Peter T. Scardino,Jack Cuzick,G. Fisher,Matthew Parker,Christopher S. Foster,Daniel M. Berney,Gyula Kovacs,Colin Cooper +18 more
TL;DR: The observations support the view that ERG gene alterations represent an initiating event that promotes clonal expansion initially to form regions of epithelial atypia and have important implications for the design of experiments investigating the clinical significance and mechanism of development of individual prostate cancers.